High performance plasma amyloid-β biomarkers for Alzheimer's disease - PubMed (original) (raw)

. 2018 Feb 8;554(7691):249-254.

doi: 10.1038/nature25456. Epub 2018 Jan 31.

Naoki Kaneko 2, Victor L Villemagne 3 4, Takashi Kato 1 5, James Doecke 6, Vincent Doré 3 6, Chris Fowler 4, Qiao-Xin Li 4, Ralph Martins 7, Christopher Rowe 3 4, Taisuke Tomita 8, Katsumi Matsuzaki 9, Kenji Ishii 10, Kazunari Ishii 11, Yutaka Arahata 5, Shinichi Iwamoto 2, Kengo Ito 1 5, Koichi Tanaka 2, Colin L Masters 4, Katsuhiko Yanagisawa 1

Affiliations

High performance plasma amyloid-β biomarkers for Alzheimer's disease

Akinori Nakamura et al. Nature. 2018.

Abstract

To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are expected to be most efficacious at the earliest and mildest stages of the disease, supportive biomarker information is necessary. The only validated methods for identifying amyloid-β deposition in the brain-the earliest pathological signature of Alzheimer's disease-are amyloid-β positron-emission tomography (PET) imaging or measurement of amyloid-β in cerebrospinal fluid. Therefore, a minimally invasive, cost-effective blood-based biomarker is desirable. Despite much effort, to our knowledge, no study has validated the clinical utility of blood-based amyloid-β markers. Here we demonstrate the measurement of high-performance plasma amyloid-β biomarkers by immunoprecipitation coupled with mass spectrometry. The ability of amyloid-β precursor protein (APP)669-711/amyloid-β (Aβ)1-42 and Aβ1-40/Aβ1-42 ratios, and their composites, to predict individual brain amyloid-β-positive or -negative status was determined by amyloid-β-PET imaging and tested using two independent data sets: a discovery data set (Japan, n = 121) and a validation data set (Australia, n = 252 including 111 individuals diagnosed using 11C-labelled Pittsburgh compound-B (PIB)-PET and 141 using other ligands). Both data sets included cognitively normal individuals, individuals with mild cognitive impairment and individuals with Alzheimer's disease. All test biomarkers showed high performance when predicting brain amyloid-β burden. In particular, the composite biomarker showed very high areas under the receiver operating characteristic curves (AUCs) in both data sets (discovery, 96.7%, n = 121 and validation, 94.1%, n = 111) with an accuracy approximately equal to 90% when using PIB-PET as a standard of truth. Furthermore, test biomarkers were correlated with amyloid-β-PET burden and levels of Aβ1-42 in cerebrospinal fluid. These results demonstrate the potential clinical utility of plasma biomarkers in predicting brain amyloid-β burden at an individual level. These plasma biomarkers also have cost-benefit and scalability advantages over current techniques, potentially enabling broader clinical access and efficient population screening.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Arch Neurol. 2011 Sep;68(9):1137-44 - PubMed
    1. Alzheimers Dement. 2014 Jan;10(1):115-31 - PubMed
    1. Nat Rev Neurol. 2017 Sep 29;13(10 ):612-623 - PubMed
    1. Alzheimers Dement. 2013 May;9(3):251-61 - PubMed
    1. Ann Neurol. 2009 Apr;65(4):403-13 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources